Trial Profile
Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Dec 2020 Status changed from active, no longer recruiting to completed.
- 30 Jun 2020 Planned End Date changed from 1 May 2020 to 1 May 2021.
- 30 Jun 2020 Planned primary completion date changed from 1 May 2020 to 1 May 2021.